RETINOPATHY OF PREMATURITY (ROP)

Introduction and Definition of Retinopathy of Prematurity (ROP)

Retinopathy of Prematurity, commonly abbreviated as ROP, stands as one of the most significant sight-threatening disorders encountered in the neonatal period, exclusively affecting premature infants. This complex condition involves the abnormal development of blood vessels within the retina, the highly specialized, light-sensitive tissue lining the back of the eye. ROP is fundamentally a disease of retinal vascularization disruption, occurring because the natural process of vessel growth that normally completes in utero is interrupted by premature birth. The severity of ROP ranges dramatically, from mild, spontaneously resolving changes that leave no lasting visual deficit, to aggressive forms that lead rapidly to retinal detachment and irreversible blindness. Given that the incidence of premature birth continues to pose a major challenge in modern medicine, understanding, detecting, and treating ROP remains a critical imperative for pediatric ophthalmologists and neonatologists globally. The disorder disproportionately impacts infants born significantly early, specifically those before 32 weeks of gestation, or those with an extremely low birth weight, typically defined as less than 1500 grams, though surveillance protocols often extend to other high-risk groups (1).

The core threat posed by ROP lies in its potential for progressive deterioration. In a normal-term infant, retinal blood vessels fully mature and reach the periphery of the retina by the time of delivery. However, in premature infants, this crucial vascular development is incomplete, leaving a peripheral zone of the retina that remains avascular, or lacking blood supply. It is within this avascular zone that the pathological processes characteristic of ROP initiate. The initial stages involve compensatory attempts by the body to revascularize the area, but these efforts often result in the proliferation of abnormal, fragile, and leaky vessels, referred to as neovascularization. This abnormal blood vessel growth is the hallmark of ROP and is the primary mechanism through which the disease exerts its damaging effects. These fragile vessels frequently hemorrhage or leak fluid, contributing to retinal edema and inflammation. Most critically, they stimulate the formation of dense fibrous scar tissue, setting the stage for mechanical damage (3).

Statistically, ROP represents a major public health concern closely tied to advances in neonatal care. While improved survival rates for extremely premature infants have been achieved through sophisticated neonatal intensive care unit (NICU) management, these same advancements have inadvertently increased the population at risk for developing ROP. Estimates suggest that ROP affects a substantial number of infants globally, with figures in the United States alone indicating an incidence impacting approximately 14,000 to 16,000 infants annually (2). Although the majority of these cases are mild and regress spontaneously without permanent visual impairment, a crucial subset develops severe, sight-threatening disease requiring urgent medical and potentially surgical intervention. Consequently, rigorous screening protocols and timely intervention are paramount to mitigating the long-term impact of ROP. The successful management of this condition relies heavily on a coordinated, multidisciplinary approach involving neonatologists managing systemic factors and ophthalmologists performing meticulous, serial retinal examinations (4).

Pathophysiology and Mechanism of ROP Development

The underlying pathophysiology of Retinopathy of Prematurity is complex, traditionally understood through a two-phase model correlating retinal development with the premature infant’s unique extrauterine environment. Phase I, often termed the vaso-obliteration or suppression phase, begins immediately following premature birth. Normally, during the third trimester of gestation, the developing retina experiences a relatively low oxygen environment compared to the external world, which drives the orderly growth of blood vessels toward the periphery. When the premature infant is delivered, they are often exposed to high supplemental oxygen concentrations in the NICU, crucial for systemic survival. This hyperoxic environment, however, paradoxically signals the existing, partially developed retinal vessels to constrict and regress, leading to a profound cessation of normal vessel growth and the creation of an expanded avascular periphery. This interruption of normal development is the foundational injury that predisposes the retina to subsequent pathology.

Phase II, the proliferative or neovascularization phase, is triggered by the subsequent relative hypoxia experienced by the peripheral avascular retina, which occurs as the infant stabilizes and supplemental oxygen is gradually weaned or reduced. The rapidly metabolizing neural retina in the periphery is now critically oxygen-starved due to the lack of blood supply initiated during Phase I. This severe peripheral hypoxia acts as an overwhelmingly powerful stimulus for the production and release of potent vascular growth factors, most notably Vascular Endothelial Growth Factor (VEGF). High local levels of VEGF are released by the oxygen-starved tissue in an attempt to stimulate blood vessel growth into the avascular periphery. However, instead of orderly, normal vessel growth, this surge of VEGF leads to unchecked, disorganized proliferation of new, weak, and highly abnormal blood vessels, known as pathological neovascularization.

The destructive cascade in ROP stems primarily from the instability and growth pattern of these new abnormal vessels. These vessels lack the structural integrity of normal vasculature and are highly prone to leakage, causing retinal edema and hemorrhage. Moreover, these neovascular complexes are inextricably linked with the growth of fibrovascular tissue. This fibrous component is highly contractile and possesses immense tensile strength. As the infant matures and this scar tissue contracts, it exerts powerful mechanical forces, pulling tangentially and perpendicularly on the delicate sensory retina. This traction can cause the retina to become severely distorted, leading to macular dragging and visual impairment, or, in the most advanced stages, result in a complete tractional retinal detachment, which represents the final, tragic pathway to irreversible blindness in ROP. The rapidity and intensity with which an infant progresses through these phases define the classification of ROP and dictate the urgency of monitoring and therapeutic intervention (3).

Primary Risk Factors and Vulnerable Populations

While prematurity itself is the absolute prerequisite for ROP development, the clinical course and severity of the disease are profoundly influenced by several interconnected risk factors related to the infant’s birth status and subsequent NICU course. The two most critical and highly correlated risk factors are low birth weight (LBW) and extremely low gestational age (GA). Infants born weighing less than 1500 grams, or those delivered before 32 weeks of gestation, constitute the primary surveillance population because their retinal vasculature is significantly less mature and thus highly susceptible to the disruptive environmental changes encountered outside the womb. The risk increases exponentially with decreasing size and age; for instance, infants weighing less than 1000 grams have a substantially higher incidence of severe, requiring treatment ROP compared to those weighing between 1250 and 1500 grams (2).

Beyond the fundamental metrics of birth weight and gestational age, the management and medical instability of the premature infant introduce several secondary, yet potent, risk factors. The most historically significant systemic factor is the requirement for supplemental oxygen therapy. While oxygen is lifesaving for preventing systemic hypoxia and ensuring organ survival, its high concentration and fluctuation must be tightly controlled. The current understanding emphasizes that wide fluctuations between hyperoxia (high oxygen) and hypoxia (low oxygen) are believed to be more damaging to the developing retina than sustained, stable saturation within established safe ranges (typically 88–92%). Other critical medical interventions and conditions that significantly increase ROP risk include severe respiratory distress syndrome, prolonged mechanical ventilation, repeated episodes of apnea and bradycardia, and significant systemic inflammation caused by neonatal sepsis or infection.

Furthermore, conditions related to the overall physiological instability of the premature infant contribute significantly to the susceptibility of the developing retina. These include chronic factors such as inadequate postnatal weight gain and nutritional status, which reflect a failure to provide the necessary metabolic building blocks for healthy retinal development. Acute factors such as repeated blood transfusions, which are often markers of underlying severe anemia or systemic instability, have also been implicated as independent risk factors. It is the cumulative burden of these systemic stresses—including severe acidosis, hypercapnia, and intraventricular hemorrhage (IVH)—coupled with the inherent immaturity of the retina, that determines whether an infant develops mild, moderate, or aggressive ROP. Therefore, effective risk mitigation requires not only careful ophthalmologic screening but also meticulous, preventative neonatal care aimed at optimizing systemic stability, minimizing infectious complications, and ensuring consistent oxygen saturation and nutritional support.

Stages and Zones of ROP Classification

To facilitate standardized diagnosis, prognosis, and treatment decisions, ROP is classified according to the International Classification of Retinopathy of Prematurity (ICROP). This universally recognized system defines the severity of the disease based on three parameters: the location (Zone), the extent of the disease (Stage), and the presence of Plus Disease (a measure of vascular abnormality in the posterior pole). Accurate identification of these parameters is essential for determining the appropriate timing and type of intervention. The location, or Zone, describes how far the abnormal vascular growth has progressed toward the periphery of the retina, measured concentrically from the optic nerve. Zone I is the most posterior and central area, involving the macula and optic nerve head, representing the most severe location because the retina is minimally vascularized. Zone II extends circumferentially beyond Zone I toward the nasal periphery, and Zone III encompasses the most anterior, temporal crescent of the retina. Disease located in Zone I or posterior Zone II carries the highest risk of rapid progression and blindness.

The Stage of ROP describes the actual structural changes observed at the junction between the vascularized central retina and the avascular peripheral retina. There are five main stages, progressing in severity. Stage 1 is the mildest form, characterized only by a faint, flat demarcation line separating the vascular and avascular retina. This stage often regresses spontaneously without intervention. Stage 2 involves the demarcation line growing into a distinct, elevated ridge, which is wider and three-dimensional, indicating increased proliferative activity. Stage 3 is the critical point where the abnormal blood vessels (neovascularization) begin to grow out of the ridge, often forming a “popcorn” appearance, and extend into the vitreous humor, signifying a high risk for subsequent traction and retinal detachment. Once Stage 3 ROP is identified in specific zones or with associated Plus Disease, treatment is usually indicated to prevent further deterioration.

The progression to Stage 4 signifies partial retinal detachment, where the contracting fibrovascular tissue begins to pull the retina off its underlying support. This stage is subcategorized as Stage 4A (extra-foveal detachment, where the macula, or center of vision, is spared) or Stage 4B (involving the fovea, which severely compromises central vision). Finally, Stage 5 represents total retinal detachment, often appearing as a fixed, funnel-shaped configuration behind the lens, resulting in complete, irreversible blindness. Crucially, the presence of “Plus Disease” indicates a severe, rapid, and aggressive form of ROP (AP-ROP), characterized by marked engorgement and tortuosity (twisting) of the posterior retinal blood vessels, signaling significant vascular shunting and high risk of rapid progression. When Stage 3 ROP is accompanied by Plus Disease, or any ROP is found in Zone I, it meets the criteria for Type 1 ROP, often referred to historically as Threshold Disease, requiring immediate therapeutic intervention (4).

Clinical Detection and Ophthalmologic Examination Protocols

Early and accurate detection of ROP is the cornerstone of successful management, as timely treatment can effectively halt the progression of the disease and preserve functional vision. ROP is routinely detected through specialized, serial ophthalmologic examinations performed by experienced pediatric ophthalmologists or trained retina specialists using indirect ophthalmoscopy. This technique is necessary because it allows the specialist to view the entire peripheral retina, which is often difficult to visualize in tiny, premature infants. To facilitate this crucial examination, the infant’s pupils must be maximally dilated using a specific regimen of topical eye drops, and specialized tools, such as a lid speculum and scleral indentation, are often employed to bring the far peripheral retina into the examiner’s view. This procedure, while essential, requires significant expertise and gentleness, given the fragility of the infant.

Screening protocols are meticulously timed based on the infant’s gestational age (GA) at birth, rather than chronological age alone. The initial examination typically occurs between 4 to 6 weeks of chronological age, or when the infant reaches a postmenstrual age (PMA) of 31 to 32 weeks, whichever is later. This specific window is chosen because the pathological neovascularization of ROP rarely develops before this postmenstrual age, but once initiated, it can progress with alarming speed. The frequency of subsequent examinations—which can be weekly, bi-weekly, or less frequent—is strictly dictated by the initial findings (the zone and stage of ROP observed) and the ophthalmologist’s assessment of the risk of progression. Infants who demonstrate fully vascularized retinas to Zone III, a key developmental milestone, are typically deemed no longer at risk for developing sight-threatening ROP, and examinations can be safely discontinued.

During the examination, the ophthalmologist systematically documents the findings according to the ICROP classification, noting the location (Zone I, II, or III), the severity (Stage 1 through 5), and the presence or absence of the ominous Plus Disease. Detailed drawing or, increasingly, wide-field digital retinal photography (telemedicine screening), is used to create a permanent record and track the subtle progression of the disease over time, which is essential for determining the treatment threshold. The decision to initiate treatment is based on specific high-risk criteria, generally defined as Type 1 ROP: Stage 3 ROP in Zone I (with or without Plus Disease), any ROP in Zone I with Plus Disease, or Stage 3 ROP in posterior Zone II with Plus Disease. Adherence to these standardized screening guidelines, such as those established by major international bodies, ensures that infants at the highest risk are identified and treated before irreversible damage to the central retina occurs (4).

Treatment Modalities: Laser Therapy and Anti-VEGF Agents

Once ROP progresses to a stage where it threatens vision (Type 1 ROP or Threshold Disease), intervention is mandatory and must be executed promptly, typically within 48 to 72 hours of diagnosis, to prevent the progression to retinal detachment. The primary goals of treatment are to halt the release of excessive Vascular Endothelial Growth Factor (VEGF) and other pro-angiogenic factors originating from the ischemic peripheral retina, thereby stopping the abnormal neovascular proliferation. Historically, the standard treatment has been ablation of the avascular retina, most commonly achieved using laser photocoagulation (4).

Laser photocoagulation involves directing a precise laser beam through the pupil to the peripheral, avascular portion of the retina. The energy from the laser creates tiny, controlled burns that intentionally destroy the oxygen-starved tissue in the periphery. By destroying this tissue, the powerful stimulus for VEGF production is eliminated or significantly reduced, effectively starving the abnormal proliferative vessels of their growth signal. This process stops the progression of neovascularization and encourages the existing abnormal vessels to regress and flatten. Laser therapy is highly successful in preventing further progression in the majority of treated cases, provided it is performed timely and comprehensively. The procedure is typically performed under general anesthesia or deep sedation, given the necessity of absolute immobility and precision required to treat the delicate and far peripheral retina of a fragile infant.

A newer, highly effective therapeutic option involves pharmacologic intervention using anti-VEGF agents, most commonly bevacizumab or ranibizumab. These agents are monoclonal antibodies injected directly into the vitreous humor (intravitreal injection) and work by neutralizing the excessive VEGF signals that drive the disease. Intravitreal anti-VEGF treatment has shown excellent results, particularly in aggressive posterior ROP (AP-ROP) in Zone I, offering the significant advantage of potentially allowing the retina to continue its natural process of orderly vascularization, unlike laser therapy which permanently destroys the peripheral retina. However, the use of anti-VEGF agents is monitored closely due to concerns regarding the potential for systemic absorption and the long-term effects of blocking VEGF—a vital factor in the development of other organ systems—in a rapidly developing infant. For this reason, anti-VEGF treatment is often reserved for Zone I disease or highly aggressive cases, while laser remains the standard for most Zone II Type 1 ROP (4).

Long-Term Visual Outcomes and Quality of Life Implications

The long-term prognosis for children who experience ROP varies significantly depending on the severity of the initial disease, the presence of Plus Disease, and the success of the treatment received. For the vast majority of infants who develop only mild ROP (Stages 1 and 2) that spontaneously regresses, the long-term visual prognosis is generally favorable, often similar to that of non-ROP premature or term infants. However, even these individuals require ongoing ophthalmological monitoring because prematurity itself is strongly associated with an increased risk of certain refractive errors, most notably severe myopia (nearsightedness), which necessitates specialized optical correction throughout their lives.

Conversely, infants who progress to severe, requiring treatment ROP (Type 1 or Stage 3 with Plus Disease) and those who develop Stage 4 or 5 ROP face significant lifelong visual challenges, even with successful surgical or laser intervention. While treatment is highly effective in preventing total retinal detachment, it often results in permanent changes to the retinal architecture. Eyes treated with peripheral laser ablation often develop a narrowed peripheral visual field due to the destruction of the treated tissue. Furthermore, these eyes remain at high risk for secondary complications later in childhood and adulthood, including severe strabismus (misaligned eyes), amblyopia (lazy eye) requiring patching, glaucoma (elevated eye pressure), and the development of late-onset retinal tears or detachments, which may require complex vitreoretinal surgery.

For the unfortunate subset of children who progress to Stage 5 ROP, the outcome is devastating, leading to profound and often total irreversible blindness in one or both eyes. These children face significant lifelong disability, necessitating comprehensive early intervention programs, specialized low-vision services, and specialized educational support. The devastating effect of severe ROP on a child’s vision and subsequent quality of life underscores the critical importance of the initial screening and intervention programs. Fortunately, heightened awareness among parents and medical professionals, coupled with standardized screening and improved NICU care protocols, has led to a significant decrease in the absolute rate of ROP-related blindness in developed nations, transforming what was once a leading cause of childhood blindness into a largely preventable condition when managed correctly and promptly (4).

Prevention Strategies and Future Directions

The most effective strategy against ROP is primary prevention, which focuses on two critical areas: reducing the incidence of severe prematurity and optimizing the postnatal environment for susceptible infants. Efforts to reduce preterm birth rates through improved maternal health care, management of high-risk pregnancies, and addressing socioeconomic determinants of health are paramount to reducing the overall ROP burden. Once an infant is born prematurely, prevention hinges on meticulous control of systemic factors in the NICU. Strict adherence to protocols governing oxygen saturation levels is perhaps the most critical preventive measure. Studies have demonstrated that maintaining oxygen saturation within a narrow, conservative target range (e.g., 88–92%) significantly reduces the incidence of severe ROP compared to higher targets, highlighting the importance of avoiding prolonged hyperoxia while maintaining adequate systemic oxygenation.

Nutritional optimization also plays an increasingly recognized role in ROP prevention. The developing retina requires specific nutrients, including long-chain polyunsaturated fatty acids (LCPUFAs) like Docosahexaenoic Acid (DHA), which are often deficient in standard premature infant formulas because they are normally transferred rapidly during the third trimester. Research is ongoing regarding the optimal supplementation of these fatty acids, along with adequate protein intake and micronutrients such as Vitamin E and iron, which may help stabilize developing tissues and reduce oxidative stress linked to ROP pathogenesis. Furthermore, minimizing the incidence of neonatal sepsis, which acts as a powerful inflammatory trigger for ROP progression, through strict infection control practices and judicious antibiotic use, contributes significantly to ROP prevention efforts.

Future directions in ROP management are heavily focused on refining pharmacological interventions and employing advanced imaging technologies. The use of anti-VEGF agents is being actively studied to determine optimal dosing, timing, and long-term safety, aiming to maximize efficacy while minimizing systemic side effects, potentially offering a more physiological treatment option than permanent laser ablation. Additionally, advancements in wide-field digital retinal imaging (RetCam) are transforming screening processes globally. These technologies allow for high-resolution capture of the peripheral retina, enabling remote expert review (telemedicine ROP screening) and providing standardized, objective documentation, which has proven highly effective in improving the accuracy and efficiency of screening, ensuring that no high-risk infant misses the critical window for intervention. Continued research into the genetic predispositions and molecular pathways of ROP promises to unlock highly targeted, personalized therapies for the next generation of extremely premature infants.

References

• Pappas, A., & Ells, A. (2010). Retinopathy of prematurity. BMJ Clinical Evidence, 2010(2).

• American Academy of Ophthalmology. (2011). Retinopathy of prematurity. Retrieved from https://www.aao.org/eye-health/diseases/rop-retinopathy-of-prematurity

• Global ROP. (2018). What is retinopathy of prematurity (ROP)? Retrieved from https://globalrop.org/about-rop/what-is-rop/

• American Association for Pediatric Ophthalmology and Strabismus. (n.d.). Retinopathy of prematurity. Retrieved from https://www.aapos.org/terms/conditions/141